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The 32nd Annual Meeting of the Society of Critical Care
Medicine was once again a well attended and very
interesting meeting. The distinguished faculty of well
recognized clinical and basic scientists from all parts of the
world presented multiple sessions highlighting the
tremendous advances being made in our understanding and
treatment of a wide variety of problems encountered in
critically ill patients. In addition, more than 600 free
communications were presented. These were too wide to be
covered in the present report. Rather, we focus on the seven
outstanding plenary sessions in which distinguished
speakers shared their views on the present and future of
critical care practice and research.
Proteomics, system biology and the future of
drug design
Michael B Yaffe (Cambridge, MA, USA)
In his lecture, Michael Yaffe alluded to how fundamental
science may help in the development of new therapeutic
agents. In the past, the search for new drugs was based on
random selection of drugs of natural sources, which were
secondary tested in all possible models. When the drug was
proven to have efficacy, its chemical structure was isolated
and the drug was then synthesized. Using this method,
unfortunately, the rate of drug discovery has decreased. A
more rational approach would be to take into account our
understanding of the mechanism of diseases in order to
identify target signalling pathways. Use of genomics to
identify gene expression of cells in different conditions is
unlikely to be helpful because the responses to several
stimuli are often similar. For example, gene expression in
macrophages is similar following stimulation by Gram-
negative bacteria, Gram-positive cocci and mycobacteria.
Proteomics may be more helpful in identifying regulatory
pathways. Proteomics covers thousand of proteins acting in
a changing environment, and hence it is important to identify
how and why several proteins are interrelated and interplay in
regulatory and/or pathophysiological processes. This leads to
the possibility of identifying critical nodes in models and
definition of where drugs are likely to act.
Innate immunity and sepsis
Thierry Calandra (Lausanne, Switzerland)
Thierry Calandra reviewed the mechanisms involved in innate
immunity, with a special emphasis on the Toll-like receptor.
He also stressed the important role played by the pituitary
axis in the modulation of inflammation. In this context, the
macrophage inhibitory factor (MIF) appears to be crucial. MIF
is high in patients surviving sepsis, and the administration of
MIF increases survival in experimental models. Interestingly,
MIF is implicated in the hypothalamic–pituitary–adrenal axis,
being present in the adrenal cortex, whereas dexamethasone
induces MIF secretion.
Multiple organ success
Mervyn Singer (London, England)
In a rather provocative talk, Mervyn Singer defended the
concept of ‘multiple organ success’. There is no doubt that
early haemodynamic resuscitation using the so-called ‘early
goal-directed therapy’ approach is crucial in severe sepsis
and septic shock, but what about late optimization? The
classic appreciation of the pathogenesis of multiple organ
failure is of a succession of events that lead from
microcirculatory alterations and systemic inflammation to
mitochondrial inhibition and shutdown, resulting in cellular
bioenergetic failure and finally multiple organ failure.
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Nevertheless, a recent histological autopsy study failed to
show dramatic histological lesions in patients dying from
septic shock. There was little cell death and no correlation
between histological findings and the severity of septic
shock. Sepsis-induced mitochondrial inhibition explains low
oxygen consumption in the presence of high tissue oxygen
tension, as reported in experimental work. This decrease in
oxygen consumption could represent an adaptive response
to sepsis; this is because it has been described in hypoxic
conditions, in which the decrease in oxygen consumption
was the result of a decrease or abolition of nonessential cell
functions, and preservation of vital functions that protect cell
integrity. In this context, pushing metabolism by exogenous
interventions may be deleterious.
ARDS physiology: an update
Luciano Gattinoni (Milano, Italy)
Mortality related to adult respiratory distress syndrome
(ARDS) ranges from 35% to 65%. Substantial progress has
been made in our understanding of how mechanical stress
can injure the lung, both by altering barrier properties of the
pulmonary endothelium and epithelium and by stimulating
proinflammatory responses of macrophages and neutrophils,
leading to the release of inflammatory mediators either in the
alveolar space or in the systemic circulation. Two major
determinants of lung injury associated with mechanical
ventilation have been clearly identified, namely high
pressure/high volume and the shear forces caused by
intratidal collapse and opening of the alveoli. The lung
protective strategy aims to reduce the impact of both of these
determinants. Many experimental animal studies have
addressed these concepts. Luciano Gattinoni discussed more
particularly the type of animal models used in these
experimental studies, specifically the size of the animals (mice
versus sheep) and whether the lungs were ‘preinjured’ before
mechanical ventilation was applied. The clinical relevance of
experimental ventilator-induced lung injury recently received a
resounding illustration from the ARDS Network Trial, which
showed a 22% reduction in mortality in patients with ARDS
when lung mechanical stress was lessened by tidal volume
reduction during mechanical ventilation. Nevertheless, in that
study, the researchers did not apply a ‘full’ lung protective
strategy and did not take shear forces into account. Gattinoni
reminded us of the concept of baby lung in ARDS and the
potential deleterious effect of positive end-expiratory pressure
application, leading to hyperinflation in healthy parts of the
lungs. In this context, the use of pressure–volume curve
monitoring at the bedside (especially, identifying the presence
or absence of a lower inflection point) could provide some
information on the morphology of the lung injury. Finally, in
response to the recent meta-analysis conducted by Eichacker
and coworkers [1], Gattinoni elegantly demonstrated, using
the ARDS Network Trial data, that the decrease in mortality in
patients ventilated with the protective strategy was due to the
reduction in tidal volume rather than any potential effect on
airway pressure.
New advances in the resuscitation of surgical
patients
Elliot Bennett Guerrero (New York City, USA)
In his lecture, Bennett Guerrero revealed how perioperative
haemodynamic optimization in high-risk surgical patients is
beneficial in terms of morbidity and mortality, provided that
the optimization protocol is well defined and standardized. In
this context, the study conducted by Sandham and
coworkers [2] was commented on and criticized. The
absence of a well standardized protocol and the lack of a
significant increase in oxygen transport in the protocol group
before surgery, the low mortality rate in both groups, and the
low recruitment rate were highlighted. In view of these points,
it appears that the only conclusion that we can draw from the
study is that, even in this population with a low mortality rate,
the insertion of a pulmonary arterial catheter is not associated
with an increase in mortality. During the perioperative period,
the emphasis was placed on a more proactive (as opposed
to reactive) approach by the anaesthesiologist (e.g. in face of
the appearance of systemic hypotension). The choice of fluid
for resuscitation appears to be of importance. In a study
including 200 cardiac surgery patients, the use of
hydroxyethyl starch in balanced solution for perioperative
haemodynamic optimization was associated with less
postoperative pain and nausea, less coagulation disorders,
and improvement in renal function as compared with the use
of hydroxyethyl starch in saline solution.
Endocrine changes in the critically ill: to treat
or not to treat?
Greet Van den Berghe (Leuven, Belgium)
Until now, several experimental studies using a therapeutic
approach aimed at normalizing the endocrine response have
failed to demonstrate efficacy. However, interest in such
interventions was recently renewed by the demonstration of
the beneficial effects of tight control of glucose levels by high
doses of insulin, and of enhancing adrenal function in relative
adrenal insufficiency by administering low doses of
hydrocortisone. Greet Van den Berghe addressed this
apparent dilemma. The endocrine response to acute illness is
biphasic. The acute phase is characterized by a decrease in
growth hormone, and a decrease in tri-iodothyronine (T3) with
an increase in reverse T3, whereas thyroxin-releasing
hormone levels are constant; adrenocorticotrophic hormone
(ACTH) is increased and cortisol is stable. On the contrary,
in protracted illness, growth hormone increases and T3
decreases markedly, whereas reverse T3 is stable and
thyroxin-releasing hormone is decreased; ACTH and cortisol
are both low. Are these alterations adaptive (and hence
protective), or do they participate in multiple organ failure?
New animal models reproducing these late alterations are
currently being developed, and such models will help us to
answer the burning question – should we treat endocrine
alterations in critically ill patients?195
Changing physician behaviour in the
intensive care unit
Deborah Cook (Hamilton, ON, Canada)
Changing the behaviour of physicians is a difficult process
that involves a number of steps. First, we should understand
our environment and our current behaviour. Second, we must
be explicit about the target behaviour to be changed. This
aspect is essential and can be addressed by successively
raising the following questions. What aspect of behaviour
should be changed? Who should be encouraged to change
their behaviour (individuals have different threshold for
different things – there are innovators and laggers)? Where
should changes be made (in meetings or teaching at the
bedside)? How (driving versus restraining force) should
changes be instituted? Finally, why should the specific
behaviour be changed? Education is fundamental because
changes are made by groups, not by individuals.
Improvement initiatives should be implemented, with
feedback. Do not hesitate to use own data to sensitize your
group to their actual behavior. At the end, an evaluation
should again be performed to assess the effectiveness of the
changes, preferably using a checklist to evaluate the
application of the proposed changes and to establish the
reasons why the changes were ultimately not applied.
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